Monograph
C08DA01 - Verapamil |
Probably porphyrinogenic |
PRP |
Rationale
Substrate of several CYPs, including 3A4. Potent CYP 3A4 inhibitor. Autoactivator of CYP 2B6, probably quantitatively insignificant. Some clinical experience of tolerance. Two references state (probable) non-porphyrinogenicity.
Chemical description
Verapamil / norverapamil: Phenylalkylamine derivatives with calcium antagonistic action. Metabolized by CYPs 2C8, 3A4, 3A5, 2C9, 2E1, 1A2, 2B6, 2C19. Inhibitor of CYPs 2C8, 1A2, 2C9, 3A4 (potent) 2D6, 2C19. Autoactivator of CYP 2B6. MFM James, RJ Hift. Porphyrias. Br J Anaesth 2000; 85, 143-53: use with care. Thunell, patient report (n=2): tolerated. Andersson, patient reports: tolerated (n=4). South African list: use with care French list: use. Kauppinen and Mustajoki. Prognosis of acute porphyria: Occurrence of acute attacks, precipitating factors,and assocciated diseases. Medicine 1992; 71, 1-13 : tolerated (n=1).
IPNet drug reports
Uneventful use reported in 4 patients with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
© NAPOS 2025